Skip to main content
SpringerLink
Log in

Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease

  • Invited Review
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

This brief report focuses on the evaluation and diagnosis of clinically localized renal masses in children and adults with Von Hippel–Lindau (VHL) disease. Counseling considerations pertinent to the urologists, medical oncologists, and multidisciplinary teams involved in the care of these patients are addressed. As practice patterns regarding the evaluation and management of VHL tumors can vary considerably, this report aims to provide guidance on some of the controversies associated with the diagnostic evaluation and initial management of localized renal masses in VHL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Linehan WM, Lerman MI, Zbar B (1995) Identification of the von Hippel–Lindau (VHL) gene: its role in renal cancer. JAMA J Am Med Assoc 273(7):564–570. https://doi.org/10.1001/jama.1995.03520310062031

    Article  CAS  Google Scholar 

  2. Maher ER, Neumann HPH, Richard S (2011) von Hippel–Lindau disease: a clinical and scientific review. Eur J Hum Genet 19(6):617–623. https://doi.org/10.1038/ejhg.2010.175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS (2017) A review of von Hippel–Lindau syndrome. J Kidney Cancer VHL 4(3):20. https://doi.org/10.15586/jkcvhl.2017.88

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15(1):55–64. https://doi.org/10.1038/nrc3844

    Article  CAS  PubMed  Google Scholar 

  5. Binderup MLM, Jensen AM, Budtz-Jørgensen E, Bisgaard ML (2017) Survival and causes of death in patients with von Hippel–Lindau disease. J Med Genet 54(1):11–18. https://doi.org/10.1136/jmedgenet-2016-104058

    Article  PubMed  Google Scholar 

  6. Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE (2015) Implications of von Hippel–Lindau syndrome and renal cell carcinoma. J Kidney Cancer VHL 2(4):163. https://doi.org/10.15586/jkcvhl.2015.41

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rednam SP, Erez A, Druker H et al (2017) von Hippel–Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23(12):e68–e75. https://doi.org/10.1158/1078-0432.CCR-17-0547

    Article  CAS  PubMed  Google Scholar 

  8. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B (1995) von Hippel–Lindau disease: genetic, clinical, and imaging features. Radiology 194(3):629–642. https://doi.org/10.1148/radiology.194.3.7862955

    Article  CAS  PubMed  Google Scholar 

  9. Maher ER (2018) Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol 36(12):1891–1898. https://doi.org/10.1007/s00345-018-2288-5

    Article  PubMed  PubMed Central  Google Scholar 

  10. Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77(283):1151–1163. https://www.ncbi.nlm.nih.gov/pubmed/2274658. Accessed 27 Aug 2019

  11. Hes FJ, van der Luijt RB, Lips CJ (2001) Clinical management of von Hippel–Lindau (VHL) disease. Neth J Med 59(5):225–234. https://www.ncbi.nlm.nih.gov/pubmed/11705642. Accessed 27 Aug 2019

  12. Nielsen SM, Rhodes L, Blanco I et al (2016) von Hippel–Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol 34(18):2172–2181. https://doi.org/10.1200/JCO.2015.65.6140

    Article  CAS  PubMed  Google Scholar 

  13. Lonser RR, Glenn GM, Walther M et al (2003) von Hippel–Lindau disease. Lancet (London, England) 361(9374):2059–2067. https://doi.org/10.1016/S0140-6736(03)13643-4

    Article  CAS  Google Scholar 

  14. HL family alliance: the VHL handbook: what you need to know about VHL: a reference handbook for people with von Hippel–Lindau disease, their families, and support personnel. Boston, MA 2014 VHL Family Alliance. No Title

  15. Balshem H, Helfand M, Schünemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 64(4):401–406. https://doi.org/10.1016/j.jclinepi.2010.07.015

    Article  PubMed  Google Scholar 

  16. Lonser RR, Glenn GM, Walther M et al (2003) von Hippel–Lindau disease. Lancet, vol 361. Elsevier Limited, Amsterdam, pp 2059–2067. https://doi.org/10.1016/S0140-6736(03)13643-4

    Chapter  Google Scholar 

  17. Binderup ML, Bisgaard ML, Harbud V et al (2013) von Hippel–Lindau disease (vHL): national clinical guideline for diagnosis and surveillance in Denmark. Dan Med J 60(12):B4763. https://www.embase.com/search/results?subaction=viewrecord&from=export&id=L370377660. Accessed 27 Aug 2019

  18. Kruizinga RC, Sluiter WJ, de Vries EGE et al (2014) Calculating optimal surveillance for detection of von Hippel–Lindau-related manifestations. Endocr Relat Cancer 21(1):63–71

    Article  Google Scholar 

  19. (2018) ACR manual on contrast media version 10.3, 2018, pp 81–87

  20. Thompson RH, Hill JR, Babayev Y et al (2009) Metastatic renal cell carcinoma risk according to tumor size. J Urol 182(1):41–45. https://doi.org/10.1016/j.juro.2009.02.128

    Article  PubMed  PubMed Central  Google Scholar 

  21. Smaldone MC, Kutikov A, Egleston BL et al (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118(4):997–1006. https://doi.org/10.1002/cncr.26369

    Article  PubMed  Google Scholar 

  22. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431. https://doi.org/10.1016/S0022-5347(05)00148-5

    Article  PubMed  Google Scholar 

  23. Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol 179(4):1227–1234. https://doi.org/10.1016/j.juro.2007.11.047

    Article  PubMed  Google Scholar 

  24. Jewett MAS, Mattar K, Basiuk J et al (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 60(1):39–44. https://doi.org/10.1016/j.eururo.2011.03.030

    Article  PubMed  Google Scholar 

  25. Park SW, Lee SS, Lee DH, Nam JK, Chung MK (2017) Growth kinetics of small renal mass: initial analysis of active surveillance registry. Investig Clin Urol 58(6):429–433. https://doi.org/10.4111/icu.2017.58.6.429

    Article  PubMed  PubMed Central  Google Scholar 

  26. Mason RJ, Abdolell M, Trottier G et al (2011) Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 59(5):863–867. https://doi.org/10.1016/j.eururo.2011.02.023

    Article  PubMed  Google Scholar 

  27. Pierorazio PM, Johnson MH, Ball MW et al (2015) Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM Registry. Eur Urol 68(3):408–415. https://doi.org/10.1016/j.eururo.2015.02.001

    Article  PubMed  Google Scholar 

  28. Jilg CA, Neumann HP, Gläsker S et al (2012) Growth kinetics in von Hippel–Lindau-associated renal cell carcinoma. Urol Int 88(1):71–78. https://doi.org/10.1159/000333348

    Article  CAS  PubMed  Google Scholar 

  29. Schuhmacher P, Kim E, Hahn F et al (2019) Growth characteristics and therapeutic decision markers in von Hippel–Lindau disease patients with renal cell carcinoma. Orphanet J Rare Dis 14(1):235. https://doi.org/10.1186/s13023-019-1206-2

    Article  PubMed  PubMed Central  Google Scholar 

  30. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DYT, Uzzo RG (2009) Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115(13):2844–2852. https://doi.org/10.1002/cncr.24338

    Article  PubMed  Google Scholar 

  31. Pomerri F, Opocher G, Bosco CD, Muzzio PC, Gennaro G (2015) Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel–Lindau disease. Eur Radiol 25(7):2025–2032. https://doi.org/10.1007/s00330-015-3591-9

    Article  PubMed  Google Scholar 

  32. Zhang J, Pan JH, Dong BJ, Xue W, Liu DM, Huang YR (2012) Active surveillance of renal masses in von Hippel–Lindau disease: growth rates and clinical outcome over a median follow-up period of 56 months. Fam Cancer 11(2):209–214. https://doi.org/10.1007/s10689-011-9503-5

    Article  CAS  PubMed  Google Scholar 

  33. Volpe A, Finelli A, Gill IS et al (2012) Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 62(3):491–504. https://doi.org/10.1016/j.eururo.2012.05.009

    Article  PubMed  Google Scholar 

  34. Burruni R, Lhermitte B, Cerantola Y et al (2016) The role of renal biopsy in small renal masses. Can Urol Assoc J 10(1–2):E28–E33. https://doi.org/10.5489/cuaj.3417

    Article  PubMed  PubMed Central  Google Scholar 

  35. Marconi L, Dabestani S, Lam TB et al (2016) Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 69(4):660–673. https://doi.org/10.1016/j.eururo.2015.07.072

    Article  PubMed  Google Scholar 

  36. Hes FJ, Höppener JW, Luijt RB, Lips CJ (2005) Von hippel-lindau disease. Hered Cancer Clin Pract 3(4):171–178. https://doi.org/10.1186/1897-4287-3-4-171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported in part by the National Eye Institute Grant NIH/NEI 5K08EY027464-02 for ABD.

Author information

Authors and Affiliations

  1. Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL, 33612, USA

    Jad Chahoud & Philippe E. Spiess

  2. Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL, 33612, USA

    Melissa McGettigan & Nainesh Parikh

  3. Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA

    Ronald S. Boris

  4. Center for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02139, USA

    Othon Iliopoulos

  5. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    W. Kimryn Rathmell

  6. Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA

    Anthony B. Daniels

  7. Department of Genitourinary Medical Oncology, UT MD Anderson Cancer Center, 1515 Holcombe Ave, Houston, TX, 77030, USA

    Eric Jonasch

Authors
  1. Jad Chahoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa McGettigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nainesh Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald S. Boris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Othon Iliopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Kimryn Rathmell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anthony B. Daniels
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eric Jonasch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Philippe E. Spiess
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

International VHL Surveillance Guidelines Consortium-Renal Committee

Contributions

Protocol/project development: All authors. Data evaluation: All authors. Manuscript writing/editing: All authors.

Corresponding author

Correspondence to Jad Chahoud.

Ethics declarations

Conflict of interest

Kimryn Rathmell receives clinical research funding from Peloton. All other authors have no relevant conflict to disclose.

Research involving human participants and/or animals

Not needed.

Informed consent

Not needed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chahoud, J., McGettigan, M., Parikh, N. et al. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol 39, 2409–2415 (2021). https://doi.org/10.1007/s00345-020-03441-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-020-03441-3

Keywords

Search

Navigation